ARCHERY - Artificial Intelligence Based Radiotherapy Treatment Planning for Cervical, Head and Neck and Prostate Cancer

The aim of this study is to look at whether an Artificial Intelligence (AI) based computer program can automate two components of the radiotherapy treatment pathway to a sufficient quality standard to enable its routine clinical use. The two components include the delineation (outlining) of anatomical areas that are at risk of tumour spread and at risk of radiation damage, and the definition of the position, size and shape of the radiation beams.

The AI-based computer programs have been developed to perform tasks that would normally require direct human involvement by oncologists and medical physicists. Proposed advantages include improved treatment accuracy, as well as a reduction in the time (from weeks to minutes) and human resources needed to deliver radiotherapy, which this study will test.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Cancer Of Prostate Cancer Cervix Cancer Head Neck Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genital Diseases Genital Diseases, Female Genital Diseases, Male Genital Neoplasms, Female Genital Neoplasms, Male Head and Neck Neoplasms Male Urogenital Diseases Neoplasms Neoplasms by Site Prostatic Diseases Prostatic Neoplasms Urogenital Diseases Urogenital Neoplasms Uterine Cervical Diseases Uterine Cervical Neoplasms Uterine Diseases Uterine Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Tata Medical Centre, Kolkata, India

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Consecutive patients with histologically confirmed head and neck cancers of the oropharynx, larynx, hypopharynx and nasopharynx (Stage I-III) that have given consent for radical radiotherapy.
Consecutive histologically confirmed primary cervical cancer patients (Stage IB-IIIB including pelvic node positive) that have given consent for radical radiotherapy.
Consecutive histologically confirmed primary prostate cancer patients (T1-4N0M0) that have given consent for radical radiotherapy.
Mental capacity to understand and consent to participate in the study.
Patients aged ≥18years.

Exclusion criteria

Patients requiring radiotherapy after curative surgery or surgery that is intended to remove as much of the tumour as possible.
Patients receiving palliative radiotherapy
Patients aged < 18years.

Treatment and study plan

A web-based artificial intelligence (AI) auto-planning tool

Other

The CT scan taken at the time of treatment planning is uploaded to a web server called the Radiotherapy planning assistant which automates the contouring of target organs and areas of high-risk disease as well as defining the size, shape and number of radiotherapy beams to treat the cancer. The final plan is downloaded to the local treatment planning system where the doses are recalculated and clinical peer review is undertaken before the plan can be used clinically.

In this study patients will not be treated with the AI tool but the manual plan created by the local teams.

Primary outcomes

Proportion of radiotherapy treatment plans that have contours and dosimetry that meet pre-defined criteria for clinical acceptability

Time frame: Prior to first treatment

Secondary outcomes

comparison of time and human resource requirements between producing automated radiotherapy treatment plans using artificial intelligence and producing treatment plans using the standard manual pathway

Time frame: radiotherapy plan preparation process pre treatment
Comparison of radiotherapy treatment costs using the artificial intelligence automated pathway and standard manual planning pathway

Time frame: radiotherapy treatment plan preparation process and treatment interval

Sponsors and collaborators

Lead sponsor

University College, London

Other

Collaborators

King Hussein Cancer Center
M.D. Anderson Cancer Center
Medical Research Council
Mount Vernon Cancer Centre at Mount Vernon Hospital
National Cancer Institute (NCI)
National Institutes of Health (NIH)
Rising Tide Foundation
Tata Memorial Centre
Tata Memorial Hospital
University Ghent
University of Cape Town
University of Malaya
University of Stellenbosch

Registry information

Important dates

Study start: 2023
Primary completion: 2026
Study completion: 2026
First posted: Dec 16, 2022
Registry last updated: Jul 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Active, Not Recruiting